Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with 28% YoY revenue growth, improved gross margins, and a significant increase in adjusted EBITDA. Despite a consolidated net loss, the surgical segment shows profitability and operational efficiency. The Q&A reveals strategic investments and growth in key products like Cellerate and BIASURGE. However, management's lack of clarity on future OpEx and R&D timelines is a slight concern. Overall, the positive financial metrics and growth prospects outweigh uncertainties, suggesting a positive stock price reaction in the short term.
Key Financial Performance
Net Revenue $25.8 million in Q2 2025, representing 28% growth year-over-year. Growth driven by sales of soft tissue products (28% YoY increase to $22.7 million) and bone fusion products (25% YoY increase to $3.1 million).
Gross Profit $23.9 million in Q2 2025, a 32% increase YoY. Gross margin increased by 250 basis points to 93% of net revenue, driven by increased sales of soft tissue repair products and lower manufacturing costs for CellerateRx Surgical.
Net Income (Surgical Segment) $500,000 in Q2 2025, an improvement of $2.7 million YoY. Improvement attributed to enhanced gross margins and significant operating leverage.
Segment Adjusted EBITDA (Surgical Segment) $4.7 million in Q2 2025, an increase of $3.3 million or 239% YoY. Driven by strong sales growth and operational efficiency.
Net Loss (Consolidated) $2 million in Q2 2025, a 43% improvement YoY. Improvement driven by strong performance in the Surgical segment offsetting investments in the THP segment.
Adjusted EBITDA (Consolidated) $2.7 million in Q2 2025, a 350% increase YoY. Improvement driven by strong profitability in the Surgical segment.
Cash Flow from Operating Activities $2.7 million in Q2 2025. Positive cash flow attributed to strong operational performance.
Operating Expenses $23.9 million in Q2 2025, a 14% increase YoY. Increase driven by higher direct sales and marketing spend in the Surgical segment and additional SG&A expenses in the THP segment.
Research and Development Expenses $300,000 increase in Q2 2025, a 28% increase YoY. Increase due to development of enhancements to the surgical product portfolio.
Long-term Debt $44.2 million as of June 30, 2025, compared to $30.7 million as of December 31, 2024. Increase due to financial activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Net revenue from surgical team: $25.8 million in Q2 2025, a 28% year-over-year growth.
Soft tissue products sales: $22.7 million, a 28% year-over-year increase.
Bone fusion products sales: $3.1 million, a 25% year-over-year increase.
New product initiatives: Progress on OsStic, a bioadhesive bone void filler, with two key development milestones achieved. Expected launch in Q1 2027.
Expansion of distributor network: Agreements with over 400 distributors, up from 300 last year.
New healthcare facilities: Customer base expanded to over 1,400 facilities, up from 1,100 last year.
Surgeon user base: Growth in surgeon users, including adoption by plastics, general, and vascular surgeons.
Gross margin improvement: Increased to 93% of net revenue, driven by soft tissue repair products and lower manufacturing costs.
Cash flow from operations: Generated $2.7 million in Q2 2025.
Adjusted EBITDA: $4.7 million for the Surgical segment, a 239% increase year-over-year.
THP segment investment management: Cash investment reduced to $7.5 million in H1 2025, with plans to further reduce to $5.5-$6.5 million in H2 2025.
Strategic alternatives for THP: Initiated a formal process to evaluate options, including engaging a strategic adviser.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
THP Segment Cash Investment: The company is actively managing expenses in the THP segment to reduce cash investment in the second half of 2025 to preserve capital. This indicates financial strain or challenges in sustaining the segment's operations.
Strategic Alternatives for THP: The company has initiated a formal process to evaluate strategic alternatives for the THP segment, including engaging a strategic adviser. This suggests uncertainty and potential challenges in the segment's future viability.
Interest Expense and Debt: The company reported an increase in other expenses primarily due to higher interest expenses and fees related to its CRG term loan, indicating financial pressure from debt obligations.
THP Segment Losses: The THP segment generated a net loss of $2.5 million in the second quarter, compared to a net loss of $1.3 million last year, highlighting ongoing financial challenges in this segment.
R&D and SG&A Expenses: Operating expenses increased due to higher selling, general, and administrative expenses and research and development costs, which could strain profitability if not managed effectively.
Regulatory and Development Milestones: The company is dependent on achieving key product development, clinical, and regulatory milestones for new products like OsStic, which poses risks if these milestones are delayed or unmet.
Supply Chain and Manufacturing Costs: While gross margins improved, the company remains exposed to potential risks in supply chain disruptions or increased manufacturing costs, which could impact profitability.
Market Penetration Challenges: The company is focused on increasing penetration in existing healthcare facilities and expanding its surgeon user base, which may face challenges due to competition or market saturation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Launch of OsStic: Sanara MedTech plans to launch OsStic, a structural mechanically enhanced bioadhesive bone void filler, in Q1 2027. This product targets over 100,000 periarticular fractures annually in the U.S.
THP Segment Cash Investment Reduction: The company plans to reduce cash investment in the THP segment to $5.5 million to $6.5 million in the second half of 2025, down from $7.5 million in the first half, to preserve capital.
Strategic Alternatives for THP: Sanara MedTech has initiated a formal process to evaluate strategic alternatives for its THP segment, aiming to maximize shareholder value and identify partners for future growth. The company does not anticipate material cash investments in THP after 2025.
Expansion of THP Pilot Program: The THP pilot program, which began in Q2 2025, will expand to include additional practitioners and locations in September 2025. A pilot program with a multistate Medicare Advantage payer is planned for Q4 2025.
Revenue Growth and Profitability Focus: The company aims to drive strong net revenue growth in 2025, primarily through its Sanara Surgical business, while maintaining strong profitability in this segment.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How long does it typically take for a new distributor partner to become productive in the field, and how should we think about the contribution curve from recently signed partners versus more established relationships?
A:The timing depends on the starting point in the market and whether approvals already exist. If approvals are in place, the learning curve is shorter. The company places an RSM in the market to drive education alongside the clinical team. The ramp-up time can range from days to months depending on the market and the work needed to get up to speed.
Q:How should we think about the cadence of OpEx as we move forward into 2026, specifically regarding opportunities for leverage in G&A or R&D and any one-time costs?
A:THP investment for the second half is guided between $5.5 million and $6.5 million, with additional OsStic milestones totaling EUR 2 million, though the timing is unclear. There has been some operating leverage in the first half, but no further comments on future guidance. R&D efforts are ongoing for innovation around key products.
Q:Can you provide specific growth details for the surgical segment products, particularly Cellerate, Fortify, and BIASURGE?
A:The soft tissue category, led by Cellerate and BIASURGE, has been a significant growth driver. Cellerate is the largest producer in the category, with BIASURGE quickly becoming the second largest. Both products continue to grow steadily, with significant potential for future growth.
Q:Do you have details on the number of new surgeons added, penetration in existing facilities, and feedback from clinicians?
A:The company focuses on three core areas: contracting and training quality distributors, gaining access to facilities, and expanding within those facilities. The core business remains ortho and spine, but they are expanding into other specialties like access surgeons, plastics, general, and vascular, in partnership with RSM and distributors.
Q:What is the strategic thinking behind exploring alternatives for THP instead of developing it internally?
A:The company has made significant investments in THP and believes it is a good time to seek strategic partners who can complement their efforts with additional capital. Strategic alternatives include partnerships with patient engagement, providers, payers, and product companies, not just a sale of the business.
Q:Review of Unclear Management Responses
A:Management avoided providing specific future guidance on operating expenses (OpEx) beyond 2026 and the exact timing of OsStic milestones. Additionally, while they mentioned ongoing R&D efforts, no detailed plans or timelines were shared.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BIASURGE facility
CellerateRx BIASURGE
Copilot app
EMR
Executive Officer
Research Division
Sanara segment
Scientific
THP Copilot
THP segment
THP technology
acquisition CarePICS
addition connection
care facility
cash investment
connection acquisition
development milestone
experience
functionality
health care
home
improvement profitability
insight
investment THP
level cash
month
pace progress
panelist
patient
priority
process alternative
profitability profile
respect
use
user
SMTI Transcript
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call reveals strong financial performance with a 19% revenue increase and improved margins, despite increased operating expenses. The Q&A section highlights robust product support and strategic expansion initiatives. Although guidance remains unchanged, the company's strategic focus on R&D and competitive positioning is promising. The lack of negative sentiment from analysts and no unclear management responses further support a positive outlook. However, increased expenses and debt levels pose some risks, tempering the sentiment from strong positive to positive.
Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript
Positive3-24
The earnings call summary highlights a strong financial performance with a 15% YoY increase in Q4 net revenue and a 20% growth for the full year 2025. This is attributed to successful product launches and market expansion. Despite the absence of discussions on operational updates, risks, or shareholder returns, the positive revenue performance suggests a favorable market reaction. The lack of additional insights from the Q&A section does not detract from the strong financial indicators. Therefore, a positive sentiment is justified.
Sanara MedTech Inc. (SMTI) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call showed strong financial performance with 22% revenue growth and a significant increase in operating income and net income. The company is focusing on profitable growth and has reduced cash investment in non-core areas. Despite some uncertainties in OsStic's regulatory path and unclear forward guidance, the positive financial results and strategic focus on core areas suggest a positive stock price reaction.
Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights strong financial performance with 28% YoY revenue growth, improved gross margins, and a significant increase in adjusted EBITDA. Despite a consolidated net loss, the surgical segment shows profitability and operational efficiency. The Q&A reveals strategic investments and growth in key products like Cellerate and BIASURGE. However, management's lack of clarity on future OpEx and R&D timelines is a slight concern. Overall, the positive financial metrics and growth prospects outweigh uncertainties, suggesting a positive stock price reaction in the short term.
SMTI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
